{"protocolSection":{"identificationModule":{"nctId":"NCT02419781","orgStudyIdInfo":{"id":"UMIN000015272"},"organization":{"fullName":"Hyogo Medical University","class":"OTHER"},"briefTitle":"Recovery by Endovascular Salvage for Cerebral Ultra-acute Embolism (RESCUE)-Japan RCT","officialTitle":"Recovery by Endovascular Salvage for Cerebral Ultra-acute Embolism (RESCUE)-Japan Randomized Controlled Trial"},"statusModule":{"statusVerifiedDate":"2018-02","overallStatus":"TERMINATED","whyStopped":"Evidence of thrombectomy for acute stroke was established","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2014-10"},"primaryCompletionDateStruct":{"date":"2017-03","type":"ACTUAL"},"completionDateStruct":{"date":"2017-07","type":"ACTUAL"},"studyFirstSubmitDate":"2015-01-19","studyFirstSubmitQcDate":"2015-04-14","studyFirstPostDateStruct":{"date":"2015-04-17","type":"ESTIMATED"},"lastUpdateSubmitDate":"2018-02-26","lastUpdatePostDateStruct":{"date":"2018-02-27","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR_INVESTIGATOR","investigatorFullName":"Shinichi Yoshimura","investigatorTitle":"Professor","investigatorAffiliation":"Hyogo Medical University"},"leadSponsor":{"name":"Shinichi Yoshimura","class":"OTHER"}},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"The aim of this study is to clarify the efficacy of the endovascular treatment for acute ischemic stroke patients with large vessel occlusion and are not respond to intravenous recombinant tissue plasminogen activator (rt-PA) therapy."},"conditionsModule":{"conditions":["Ischemic Stroke"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["NA"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":19,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Group with endovascular treatment","type":"ACTIVE_COMPARATOR","description":"Group with additional endovascular treatment","interventionNames":["Procedure: Rescue endovascular therapy"]},{"label":"Group without endovascular treatment","type":"ACTIVE_COMPARATOR","description":"Group without additional endovascular treatment","interventionNames":["Procedure: No endovascular therapy"]}],"interventions":[{"type":"PROCEDURE","name":"Rescue endovascular therapy","description":"endovascular treatment using any devises for acute ischemic stroke patients with large vessel occlusion and not respond to intravenous recombinant tissue plasminogen activator (rt-PA) therapy","armGroupLabels":["Group with endovascular treatment"]},{"type":"PROCEDURE","name":"No endovascular therapy","armGroupLabels":["Group without endovascular treatment"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Assessment of modified Rankin Scale shift analysis at 90 days after onset","timeFrame":"90 days"}],"secondaryOutcomes":[{"measure":"The rate of mRS 0-2 at 90 days (+/- 10 days) after onset","timeFrame":"90 days"},{"measure":"Death within 90 days (+/- 10 days) after onset","timeFrame":"90 days"},{"measure":"Revascularization rates of the target vessel at 72 hours (+/- 8 hours) after onset","description":"for CT angiography or MR angiography","timeFrame":"72 hours"},{"measure":"Symptomatic intracranial hemorrhage within 72 hours (+/- 8 hours) after onset","timeFrame":"72 hours"},{"measure":"The difference of NIHSS score between pre-treatment and at 72 hours (+/- 8 hours) after onset","timeFrame":"72 hours"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Acute ischemic stroke patients who were treated with intravenous rt-PA therapy within 4.5 hours from onset and have persistent occlusion of IC and M1 proximal portion\\* confirmed by cerebral angiography.\n\n  \\*: M1 proximal portion means the segment of MCA within 5mm from the internal carotid bifurcation.\n* Patients who can receive endovascular treatment within 8 hours after the onset.\n* Patients whose DWI-ASPECTS was 5 points and more, or CT-ASPECT was 6 points and more just before cerebral angiography.\n* Patients whose NIHSS is between 8 and 29 points.\n* Patients who are between 20 and 85 years.\n* Gender does not matter.\n* Consent of this study participants must be obtained from patients or legal representative in writing.\n\nExclusion Criteria:\n\n* Patients whose neurological symptoms improved and NIHSS is eight points and less after intravenous rt-PA therapy.\n* Patients whose mRS was 3 points and more before the onset. 3)Patients with past history of lumbar puncture or arterial puncture that were difficult of hemostasis.\n* Patients with intracranial tumor\n* Patients with hypersensitivity to contrast agent.\n* Patients with serious renal disease.\n* Patients with malignant tumor.\n* Patients with pregnancy or suspect of pregnancy, or during lactation.\n* Patients with findings of acute myocardial infarction or pericarditis after myocardial infarction.\n* Patients who cannot be followed for 3 months.\n* Patients with past history of cerebral aneurysm, cerebral arteriovenous malformation, cerebral venous thrombosis, or moyamoya disease.\n* Patients with other occlusions besides ICA or M1 proximal portion.\n* Patients with aortic dissection complicating endovascular treatment.\n* Patients with tortuous arteries that prevent the navigation of the device to the target vessel.\n* Patients considered inappropriate to participate in the study.","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","maximumAge":"85 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Shinichi Yoshimura, MD, PhD","affiliation":"Hyogo Medical University","role":"PRINCIPAL_INVESTIGATOR"}],"locations":[{"facility":"Hyogo College of Medicine","city":"Nishinomiya","state":"Hyogo","zip":"883-8501","country":"Japan","geoPoint":{"lat":34.71562,"lon":135.33199}}]},"referencesModule":{"references":[{"pmid":"34125952","type":"DERIVED","citation":"Roaldsen MB, Jusufovic M, Berge E, Lindekleiv H. Endovascular thrombectomy and intra-arterial interventions for acute ischaemic stroke. Cochrane Database Syst Rev. 2021 Jun 14;6(6):CD007574. doi: 10.1002/14651858.CD007574.pub3."}]}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000083242","term":"Ischemic Stroke"},{"id":"D000004617","term":"Embolism"}],"ancestors":[{"id":"D000020521","term":"Stroke"},{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000016769","term":"Embolism and Thrombosis"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M7474","name":"Embolism","asFound":"Embolism","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","relevance":"LOW"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"M16376","name":"Thrombosis","relevance":"LOW"},{"id":"M18818","name":"Embolism and Thrombosis","relevance":"LOW"},{"id":"T170","name":"Acute Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"browseLeaves":[{"id":"M13539","name":"Tissue Plasminogen Activator","relevance":"LOW"},{"id":"M13538","name":"Plasminogen","relevance":"LOW"}],"browseBranches":[{"abbrev":"FiAg","name":"Fibrinolytic Agents"},{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":false}